| 1 |
Zhao H, Ye TH, Gong ZY, et al. Application of lornoxicam to patient controlled analgesia in patients undergoing abdominal surgeries. Chin Med Sci J,2005,20(1):59-62.
|
| 2 |
Fisher B,Bryant J,Welmark N,et al.Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol,1997,15(7):2488-2492.
|
| 3 |
Sapunar F,Smith IE.Neoadjuvant chemotherapy for breast cancer.Ann Med,2000,32(1):43-50.
|
| 4 |
Berry DA,Cirrincione C,Henderson IC,et al.Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.JAMA,2006,295(14):1658-1667.
|
| 5 |
Giannakakou P, Poy G, Zhan Z, et al. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.Oncogene,2000,19(27):3078-3085.
|
| 6 |
Bellamy CO.p53 and apoptosis.Br Med Bull,1997,53(3):522-538.
|
| 7 |
Kandioler-Eckersberger D,Ludwig C,Rudas M,et al.TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.Clin Cancer Res,2000,6(1):50-56.
|
| 8 |
Lamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science,1987,235(4785):177-182.
|
| 9 |
MacGrogan G,Mauriac L,Durand M,et al.Primary chemotherapy in breast invasive carcinoma:predictive value of the immunohistochemical detection of hormonal receptors,p53,c-erbB-2,MiB1,pS2 and GST pi.Br J Cancer,1996,74(9):1458-1465.
|
| 10 |
Regidor PA,Regidor M,Schindler AE,et al.Aberrant expression pattern of gap junction connexins in endometriotic tissues.Mol Hum Reprod,1997,3(5):375-381.
|
| 11 |
谯建,姚珍薇,令狐华.CON43、CON26 蛋白在子宫内膜异位症中的表达及意义.实用妇产科杂志,2005,21(12):732-734.
|